anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention provides an anti-swine fever multi-epitope DNA vaccine as well as a construction method and uses thereof. The anti-swine fever multi-epitope DNA vaccine is constructed by sieving out CSFV E2 and E&lt;rns&gt; antigenicity encoding genetic fragments, incorporating with tPa signals and cloning to pVAX1 eucaryon expression vector. The vaccine is Escherichia coli D H5 [alpha] (ptPAs/[delta] E2/[delta] E&lt;rns&gt;), CCTCC, M208254. The anti-swine fever multi-epitope DNA vaccine encodes the principal epitopes and tPa signals of CSFV E2, E&lt;rns&gt; glycoprotein, which can intensify the expression amount and secretion of protective antigens and prominently enhance the immune protection effect of the DNA vaccine. The vaccine has the characteristics of low costs, stable structure, no need of cold-chain transport and cryopreservation, long storage period and great safety and effectiveness. Such anti-swine fever multi-epitope DNA vaccine immunization pigs can induce the generation of a complete protection against fatal attacks from swine fever velogen strains, can accelerate the elimination for infected virus in the immunization pigs, and can, in combination with the detection for swine fever virus specificity NS3 antibody and/or swine fever virus genomic nucleic acids in blood serum, be extensively applied to purifying, preventing and eradicating the swine fever in a pig farm.
PURPOSE:To provide a body lotion containing licorice and sodium alginate as active components, effective to swell an soften the skin and to normalize the greasy skin when applied to the skin, and exhibiting excellent effect to promote the growth of hair when applied to the scalp. CONSTITUTION:4-12 pts. wt. of licorice and 4-12 pts. wt. of sodium alginate are used as the active components, and are added with ethanol, glycerol and water as main components to obtain 100 pts.wt. of a mixture. The objective body lotion is produced by adding a small amount of perfume and antiseptic to the mixture. the lotion may be added to a shampoo or a liquid soap. Ethanol has antipyic activity by its sterilizing action. Glycerol is effective to swell the skin, prevent the chapping and cracking of the skin, and cure athlete&#39;s foot. EFFECT:It opens the pores of the skin when applied to the scalp, facilitates the absorption of the active component, and promotes the growth of hair.
PURPOSE: To obtain a solidifying agent for a silicone oil which has thixotropic properties and can gelatinize a silicone oil by using a specific organopolysiloxane having both molecular ends modified. CONSTITUTION: The agent contains an organopolysiloxane of the formula having both molecular ends modified. In the formula, R&lt;1&gt; to R&lt;4&gt; are each independently 1-6C alkyl, phenyl, or naphthyl; R&lt;5&gt; and R&lt;6&gt; are each independently a 16-600C linear or branched satd. hydrocarbon group; and r and s are each 0 or higher. Though the agent may comprise the organopolysiloxane alone, it may further contain other ingredients (e.g. a wax or an oil-gelatinizing agent) if necessary. A stable cosmetic excellent in persistence, feeling in use, etc., can be formed by incorporating the agent into a silicone oil liq. at normal temp.
The invention discloses a traditional Chinese medicine formula for treating piles. The preparation comprises an externally-washed prescription and an orally-taken prescription, wherein the externally-washed prescription and the orally-taken prescription are combined for treatment. The externally-washed medicine mainly comprises Glauber&#39;s salt, zanthoxylum, radix sileris, coptis root, houttuynia cordata thunb., nutgall and the like. With 50 grams of preparation as a reference, the content of various components is as follows: 10 grams of zanthoxylum, 10 grams of radix sileris, 10 grams of houttuynia cordata thunb., 10 grams of nutgall, 5 grams of coptis root and 5 grams of Glauber&#39;s salt. The orally-taken medicine mainly comprises sophora japonica, garden burnet, rehmannia root, peony bark, honeysuckle flower, weeping forsythia, radix sileris, gardenia, red peony root, herba schizonepetae and the like. With 150 grams of preparation as a reference, the content of various components is as follows: 15 grams of sophora japonica, 15 grams of garden burnet, 15 grams of rehmannia root, 15 grams of honeysuckle flower, 10 grams of peony bark, 10 grams of weeping forsythia, 10 grams of radix sileris, 10 grams of gardenia, 10 grams of red peony root and 10 grams of herba schizonepetae. The traditional Chinese medicine formula fetures wide medicine source, easy material acquirement, simple preparation, no toxic or side effect and remarkable curative effect, is economical and practical and is suitable for the treating various patients.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for treating TWEAK-related conditions such as cardiac, liver, kidney, lung, adipose, skeletal, muscle, nerve, bone and cartilage conditions, and a pharmaceutical agent.  &lt;P&gt;SOLUTION: TWEAK agonists or antagonists for treating TWEAK conditions and a method for identifying the same are provided. Transgenic animals expressing a TWEAK polypeptide or fragments, analogs or muteins thereof or an exogenous DNA encoding a TWEAK polypeptide are also provided. In addition, a method for diagnosing a disease caused by TWEAK expression is provided. A method for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists or antagonists is provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for reducing the chemical activity and photo activity of titanium dioxide nanoparticles.  &lt;P&gt;SOLUTION: The method comprises a step of adding a densifying agent, such as citric acid, to aqueous slurry of the titanium dioxide nanoparticles and a step of treating the aqueous slurry with a source of alumina, such as a solution of sodium aluminate, to form alumina-treated titanium dioxide nanoparticles. In one embodiment the particles are treated with a source of silica, such as a solution of sodium silicate. The nanoparticles can be treated with a source of silica and a source of alumina. The treated nanoparticles can be silanized. The titanium dioxide nanoparticles described herein are useful in cosmetic, coating and thermoplastic compositions.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
User activity including both athletic activity (e.g., running, walking, etc.) and non-athletic activity (shopping, reading articles, etc.) may be monitored and tracked by an athletic monitoring and tracking device and service. The user activity may be used to award a user with an amount of virtual currency to encourage the user to continue various activities. In one example, users may use the virtual currency to purchase or otherwise acquire various products, services, discounts and the like. A user may track an amount currency earned and/or needed relative to an amount required to acquire a desired product or service. Additionally or alternatively, a visual appearance of a user device (e.g., a watch or athletic activity band) may change based on the user&#39;s activity level, an amount of virtual currency earned and the like.
A medical information system (Fig. 2-30) and method that stores and manages patient information and that enables a patient (Fig. 2-12) and an authorized third party, such as a friend or family member, to access the patient&#39;s medical information. The presentation format, substance of the patient&#39;s medical information provided, or both are customized depending on whether the patient (Fig. 2-12), a healthcare professional (Fig. 2-16) or the third party (Fig. 2-40) is accessing the patient&#39;s medical information. The present invention also pertains to a method of subsidizing such a medical information system (Fig. 2-30) by selling advertising space in the presentation shown to the third party, patient or healthcare professional. The present invention further pertains to a patient interface appliance that includes a display containing multiple viewing fields, one of which is a general information field and one of which is an advertising field, to present information and advertisements to a user during a patient interactive session. Patient participation in conducting the survey is fostered by offering a survey completion reward to the patient upon completing the survey.
A device for use in hair treatment (e.g. highlighting) comprises a clip which may be conveniently manufactured in plastic and comprises two flat plates (1 and 2) of rectangular shape being joined by an integral hinge (3), for example of flexible plastic. The plates may be closed together by flexure about the hinge (3) and fastened in the closed position by means of a latch (4). The inner faces of each plate have an applied strip of a retentive or absorbent resilient material such as rubber or plastic foam or plastic wool (5). These absorbent strips may be secured for example by projecting spikes (6) which penetrate the strip, or may be permanently or releasably bonded to the surfaces of the plates. Tinting cream may be applied to one or both of the absorbent strips and selected tufts of hair are each held in a cream coated clip; the clips are easily placed and fastened using one hand only, allowing the other hand to keep a secure grip on the tuft of hair. &lt;IMAGE&gt;
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the heavy chain or/and the light chain comprises one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within the antibody&#39;s heavy chain and/or light chain. The invention further relates to one or more nucleic acids encoding the modified antibody according to the invention as well as a covalent conjugate comprising (i) the modified antibody according to the invention and (ii) one or more non-antibody moieties (payload(s)) covalently conjugated to the one or more first recognition site(s) either directly or via a first linker. In certain embodiments, the non-antibody moiety comprises a therapeutic entity and optionally a second linker. The present invention further relates to a method of covalently conjugating a modified antibody according to the invention to non-antibody moieties. In case the non-antibody moiety comprises a therapeutic entity, the present invention further relates to the conjugate of the modified antibody according to the invention and the therapeutic entity as pharmaceutical composition, for use as a medicament as well as for use in treating a disease.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition efficiently exhibiting various kinds of physiological activities latently possessed by seaweed of the genus Porphyra.  &lt;P&gt;SOLUTION: The Porphyra sp. protein-containing composition is obtained by adding water, a saline solution or a dilute aqueous solution of an alkali to a thallus or a dried finely granulated material of the seaweed of the genus Porphyra, extracting a soluble ingredient while carrying out wet grinding and conducting a separation treatment of the protein from the extract liquid. The extraction with the saline solution or the dilute aqueous solution of the alkali may separately be performed to provide each of separate Porphyra sp. protein-containing compositions or the operations may successively be carried out to mix each of the compositions.Thereby, the Porphyra sp. protein-containing composition is obtained. The resultant Porphyra sp. protein-containing composition has the physiological activities such as hypotensive actions, hepatic function improving actions, lipid metabolism improving actions, peripheral vasodilator actions and blood viscosity-lowering actions. Thereby, the composition is used as a food effective for health.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
An oral solid compress composition comprising a magnesium salt is provided. The composition provides a rapid dissolution of the magnesium salt, wherein not less than 75% of the magnesium salt dissolves within 45 minutes after placement in hydrochloric acid (0.1 N, 900 mL) as per USP Method &lt;711&gt;. In a particular embodiment, the magnesium salt is an inorganic salt such as MgO, Mg(OH)2, MgCl2, and others. The composition can be prepared by dry granulation, direct compression or another suitable process. The composition provides a substantially stable dissolution profile for the magnesium salt so that the dissolution profile changes only minimally even after an extended period of storage under pharmaceutically acceptable conditions when packaged in a sealed container-enclosure system. The solid composition may also exclude a cellulose-based composition. The compressed composition can be prepared and stored under anhydrous conditions.
PROBLEM TO BE SOLVED: To obtain a glycerophosphate dehydrogenase inhibitor useful as a food additive, etc., by using a specific extract of areca nut with a hydrophilic solvent as an active component. SOLUTION: An extract obtained by extracting areca nut known as a herb drug with a hydrophilic solvent is used as an active component of the objective inhibitor. The extract is one or more substances selected from NF-86I, NF-86II, NPF-86IA, NPF-86IB, NPF86II and NPF-86IIB. The glycerophosphate dehydrogenase inhibitor is usable by adding to biscuit, tablet candy, tablet drug, bread or noodle. The inhibitor has high safety and excellent glycerophosphate dehydrogenase inhibiting activity and is easily compoundable to a food and useful for the prevention and treatment of obesity. NF-86I which is one of the active components is pale yellowish brown powder (stable in powdery form), free from distinct melting point and decomposition point and composed of 56.30% carbon, 4.61% hydrogen, &lt;=0.2% nitrogen and &lt;=0.3% ash and has a molecular weight of 1,000-10,000 (by dialysis tube).
A system (100) and method for providing guidance in an ultrasound imaging procedure involves presenting graphical user interface (131) elements overlaid onto an external image of the subject&#39;s body. The system includes at least one camera (137) for capturing the external image of the subject. The system may utilize trained artificial neural network(s) (150) to identify locations in the external image that correspond to scanning zones of a scanning protocol. A probe (112) placement marker is overlaid at each identified location to indicate the position of the probe&#39;s face onto the subject&#39;s body for acquiring a target view of the internal anatomy. Additional graphical elements may be presented via the guidance interface (133) and results findings may optionally be overlaid onto the external image of the subject at the completion of the scan. In embodiments herein, imaging guidance is provided solely via the external images of the subject without displaying the ultrasound image data.
1. A method of treating patients suffering from CNS disease comprising the administration to the patent of both cabergoline and pramipexole or their pharmacologically acceptable salts. 2. A method of claim 1 for the treatment of patients suffering from Parkinson&#39;s Disease. 3. A method of claim 2 where the initial dose of cabergoline is administered to the patient at a dose of 0.5 to 1 mg/patient/day and is adjusted upward at weekly intervals to a therapeutic dosage of 2,4,6,8 or 10 mg/patient/day and where the initial dose of pramipexole is started at 0.375 mg/patient/day and is adjusted upward every 5 to 7 days to a therapeutic dosage of 3,4,5,6,or 7 mg/patient/day. 4. The method of claim 3 where the cabergoline is administered to the patient at a dose of 0.5 to 1 mg/patient/day and is adjusted upward at weekly intervals to a therapeutic dosage of 4, or 6 mg/patient/day and the pramipexole is adjusted upward weekly to a dosage of 5 or 6 mg/patient/day. 5. The method of claim 4 where the therapeutic dose of cabergoline is 6 mg/patient/day and the therapeutic dose of pramipexole s 5 mg/patient/day. 6. Use of cabergoline in combination with pramipexole or their pharmacologically acceptable salts as a medicament for use in treating Parkinson&#39;s Disease (PD). 7. A pharmaceutical composition for treatment of Parkinson&#39;s Disease (PD), comprising cabergoline in combination with pramipexole or their pharmacologically acceptable salts or pharmacologically acceptable carrier.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapy method associated with a MAdCAM (mucosal addressin cell adhesion molecule) to an inflammatory intestinal disease.  &lt;P&gt;SOLUTION: The antibody includes a human antibodies and an antigen-binding portion thereof that specifically binds to human MAdCAM and that functions to inhibit MAdCAM. The human anti-MAdCAM antibody and an antigen-binding portion thereof are provided. The antibody that is chimeric, bispecific, derivatized, a single strand antibody or a portion of a fusion protein is provided. The isolated heavy and light chain immunoglobulin derived from human anti-MAdCAM antibody and the nucleic acid molecule encoding such an immunoglobulin are provided. A method of making a human anti-MAdCAM antibody and a compositions comprising the antibody and a method of using the antibody and the composition for diagnosis and treatment are provided. A gene therapy method uses a nucleic acid molecule encoding the heavy and/or light chain immunoglobulin molecule that comprise the human anti-MAdCAM antibody.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Complex is described which is insoluble in water and aqs. fluids and which complexes halogen molecules by charge transfer or by van der Waal&#39;s forces. The complex is formed by contacting polyvinyl pyrrolidone polyamides, copolymers or polycondensates contg. (active) C with molecular I2. The complex is used to sterilise fluids which contact mucous membranes or other living tissues, render water and gases aseptic, in horticulture as fungicides and in (veterinary) medicine. They are also used in the hygiene/dermatology sectors (e.g. in soaps, pomades, toothpastes, chewing gum), all these uses involving suitable I2 concentrations. The complexes only lose a max. of 1-3% of the I2 introduced and do not alter the taste, smell or quality of any water treated although the I2 is present in the active, molecular, form.
&lt;P&gt;PROBLEM TO BE SOLVED: To contrive expansion of usage of the stems and leaves of sweet potatoes and to provide a new anti-obesity agent, by finding a new function of the stems and leaves of sweet potatoes.  &lt;P&gt;SOLUTION: The anti-obesity agent comprising a processed material of the stems and leaves of sweet potatoes is provided. This anti-obesity agent has a superior weight increase suppressing action. The anti-obesity agent of the invention also has a fat accumulation suppressing action. Accordingly, it can prevent obesity by suppressing the accumulation of fat. Furthermore, the processed material of the stems and leaves of sweet potatoes can be used also as the fat accumulation suppressing agent, because the material has the fat accumulation suppressing action.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To prepare an agent for suppressing and treating atherosclerosis having cholesterol biosynthesis inhibiting activities and hypercholesterolemia inhibiting activities by including bisphosphonate squalene synthase inhibitor. CONSTITUTION: This agent for suppressing and treating atherosclerosis includes bisphosphonate compound of the formula (R&lt;1&gt; to R&lt;4&gt; are each H, an alkyl, an aryl, ammonium, etc.; at least one of R&lt;5&gt; and R&lt;6&gt; is hydroxycarbylheterocycle, etc.), e.g. tetramethyl 1-(p-chlorophenyl)methane-1-hydroxy-1,1-diphosphonate. The compound has a methylene bonded to both phosphonate, and further at least one lipophilic group bonded to the methylene group. The agent is used for increasing a high density lipoprotein cholesterol level and is also useful for inhibition of gallstone formation, tumor treatment, pressure decrease, treatment of glycosuria, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an image divider which does not require binarization of a captured image, is not affected by scars and dirt of a film, can deal with a mixture of small images difference in size, can deal with shapes of the small images other than rectangle, and can deal with an arrangement of small images even when the small images are not in a grid shape.  &lt;P&gt;SOLUTION: A frequency distribution of image brightness constituting captured images and an average value of frequency of the brightness are obtained. The brightness having frequency exceeding the average value is detected as a background brightness to be brightness of a background part. The frequency distribution of the brightness other than the background brightness is obtained, and an arrangement of the small images in an image region of images captured on the basis of the frequency distribution is obtained. Thus, it is possible to divide small images precisely without being affected by scars or dirt of the film even when small images different in size mix, shapes of the small images are not rectangle, or the arrangement of the small images is not in the grid shape.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To provide a powdery cosmetic prepared by blending a rod-shaped powder under a specified condition, enabling uniform orientation of the rod- shaped powder on the skin when applied to the skin and reduction of rising of the white powder, excellent in adhesion and reduced in caking. CONSTITUTION:This is a powdery cosmetic containing a rod-shaped powder, a plate-shaped powder, iron oxide and a lubricant. This cosmetic contains the rod-shaped powder especially in an amount of 0.5 to 20 pts.wt. based on 100 pts.wt. cosmetic and enables orientation of the rod-shaped powder when it is applied. The rod-shaped powder is preferably selected from titanium oxide, a titanic acid salt, potassium carbonate, silica, alumina, zirconia, silicon nitride, halloysite and iron oxide. Especially, its composite powder or its surface-treated powder is preferably used. As the size of the rod-shaped powder, the short diameter, the long diameter and the ratio of the short diameter to the long diameter are preferably 0.005 to 0.5mum, &gt;=1mum and 1:10 to 1:2000 respectively.
FIELD: veterinary science, virology. SUBSTANCE: invention relates to production of vaccine preparations against reoviral tendinous synovitis in chickens and can be used for diagnostic preparations making. Strain is deposited in VGNKI collection at number &#34;VNIVIP- -DEP&#34;. Vaccine strain &#34;VNIVIP-DEP&#34; is prepared by intermitted passages in developing chicken embryos and in cultured chicken fibroblasts. Virions have spheric form, cubic symmetry, size is 65-70 nm. Nucleocapsid has RNA. In cultured cells the strain induces formation of plaques (size is 1-2 mm). Strain is reproduced in cultured chicken embryos, it induces acute infection form with expressed cytopathic effect in 2-4 days and accumulated at titers 6.0-7.0 lg TCA 50 . Strain is attenuated, it induces formation of plaques in XAO chicken embryos. Strain does not induce disease in chickens and laboratory animals at pareneteral administration in doses exceeding vaccinial dose by 100-fold. Strain does not show hemagglutinating and heme adsorbing activity. Strain shows resistance to ether and chloroform, it shows stability at 60 C for 1 h. Strain is closely related to antigens of epizootic strains of reovirus inducing diseases in poultry farmings and to the strain &#34;1133&#34;. Strain shows enhanced immunogenic activity being independently of method of its use in combination with ability to high level of reproduction in cultured cells, absence of reactivity and retention of increased thermostability. EFFECT: strain indicated above, valuable properties. 5 tbl, 3 ex